Journal
PROSTAGLANDINS LEUKOTRIENES AND ESSENTIAL FATTY ACIDS
Volume 88, Issue 1, Pages 105-114Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.plefa.2012.05.006
Keywords
Mitochondria; DHA; EPA; ALA; ARA; Brain; Neurodegeneration; Alzheimer; Brain aging; Parkinson; Huntington; Stroke; PUFA; Omega-3; Fatty acids; Docosahexaenoic acid; Eicosahexaenoic acid; Arachidonic acid; Linoleic acid; Linolenic acid; Diet; Nutrition; Clinic
Funding
- Arbeitskreis Omega-3 e.V., Frankfurt, Germany
Ask authors/readers for more resources
Mitochondrial dysfunction represents a common early pathological event in brain aging and in neurodegenerative diseases, e.g., in Alzheimer's (AD), Parkinson's (PD), and Huntington's disease (HD), as well as in ischemic stroke. In vivo and ex vivo experiments using animal models of aging and AD, PD, and HD mainly showed improvement of mitochondria] function after treatment with polyunsaturated fatty acids (PUFA) such as docosahexaenoic acid (DHA). Thereby, PUFA are particular beneficial in animals treated with mitochondria targeting toxins. However, DHA showed adverse effects in a transgenic PD mouse model and it is not clear if a diet high or low in PUFA might provide neuroprotective effects in PD. Post-treatment with PUFA revealed conflicting results in ischemic animal models, but intravenous administered DHA provided neuroprotective efficacy after acute occlusion of the middle cerebral artery. In summary, the majority of preclinical data indicate beneficial effects of n-3 PUFA in neurodegenerative diseases, whereas most controlled clinical trials did not meet the expectations. Because of the high half-life of DHA in the human brain clinical studies may have to be initiated much earlier and have to last much longer to be more efficacious. (c) 2012 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available